Search Results

You are looking at 201 - 210 of 1,243 items for :

  • Refine by Access: All x
Clear All
Full access

Michelle T. Ashworth and Adil Daud

result of a selection effect for patients with more indolent, oligometastatic disease or for more fit patients who can undergo surgery. This has not been evaluated in a prospective randomized clinical trial, and will continue to be a moving target as more

Full access

Martine Extermann

. 13 Marcantonio ER Goldman L Mangione CM . A clinical prediction rule for delirium after elective noncardiac surgery . JAMA 1994 ; 271 : 134 – 139 . 14 Inouye SK Viscoli CM Horwitz RI . A predictive model for delirium in

Full access

Scott M. Schuetze

: long-term results of the Rizzoli's 4th protocol . Eur J Cancer 2001 ; 37 : 2030 – 2039 . 37. Bacci G Picci P Ferrari S . Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients

Full access

Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Ajjai Alva, Michael Baine, Kathryn Beckermann, Maria I. Carlo, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Arpita Desai, Yasser Ged, Saby George, John L. Gore, Naomi Haas, Steven L. Hancock, Payal Kapur, Christos Kyriakopoulos, Elaine T. Lam, Primo N. Lara, Clayton Lau, Bryan Lewis, David C. Madoff, Brandon Manley, M. Dror Michaelson, Amir Mortazavi, Lakshminarayanan Nandagopal, Elizabeth R. Plimack, Lee Ponsky, Sundhar Ramalingam, Brian Shuch, Zachary L. Smith, Jeffrey Sosman, Mary A. Dwyer, Lisa A. Gurski, and Angela Motter

% CI, 2%–16%). 26 This model was validated in an independent dataset. 28 Surgical Options for Patients With Relapsed or Stage IV Disease Patients with stage IV disease also may benefit from surgery. For example, lymph nodes suspicious for

Full access

Titilayo O. Adegboyega, Jeffrey Landercasper, Jared H. Linebarger, Jeanne M. Johnson, Jeremiah J. Andersen, Leah L. Dietrich, Collin D. Driscoll, Meghana Raghavendra, Anusha R. Madadi, Mohammed Al-Hamadani, Choua A. Vang, Kristen A. Marcou, Jane Hudak, and Ronald S. Go

emphasizing the importance of NCCN Guidelines. Since 2009, NCCN Guideline compliance has been recorded by surgeons prospectively at the point of patient contact before and after surgery using electronic synoptic templates (EST). The EST is incorporated into

Full access

Abdul-Rahman Jazieh, Hanaa Bamefleh, Ahmet Demirkazik, Rabab Mohamed Gaafar, Fady B. Geara, Mansur Javaid, Jamal Khader, Kian Khodadad, Walid Omar, Ahmed Saadeddin, Hassan Al Sabe, Mohammad Behgam Shadmehr, Amgad El Sherif, Najam Uddin, Mohammad Jahanzeb, and David Ettinger

formed. The committee comprises various experts in thoracic oncology, including medical and clinical oncology, radiation oncology, pulmonology medicine, thoracic surgery, radiology, and pathology. The committee convened twice and corresponded frequently

Full access

Shailender Bhatia and John A. Thompson

as surgery or radiation therapy, may provide palliation of symptoms caused by local tumor growth, the cornerstone of treatment for metastatic melanoma is systemic therapy to address the clinical and subclinical sites of metastases. Chemotherapeutic

Full access

Al B. Benson, Michael I. D’Angelica, Daniel E. Abbott, Daniel A. Anaya, Robert Anders, Chandrakanth Are, Melinda Bachini, Mitesh Borad, Daniel Brown, Adam Burgoyne, Prabhleen Chahal, Daniel T. Chang, Jordan Cloyd, Anne M. Covey, Evan S. Glazer, Lipika Goyal, William G. Hawkins, Renuka Iyer, Rojymon Jacob, R. Kate Kelley, Robin Kim, Matthew Levine, Manisha Palta, James O. Park, Steven Raman, Sanjay Reddy, Vaibhav Sahai, Tracey Schefter, Gagandeep Singh, Stacey Stein, Jean-Nicolas Vauthey, Alan P. Venook, Adam Yopp, Nicole R. McMillian, Cindy Hochstetler, and Susan D. Darlow

this disease, patients need careful consideration of treatment choice given the risk of potential toxicities from treatment and potential benefits. Surgery Partial hepatectomy is a potentially curative therapy for patients with a solitary tumor of

Full access

Rajinder S. Grover, Kemp Kernstine, and Amrita Krishnan

performance status, and quick wound healing, which allowed her to receive chemotherapy within 4 weeks of the esophageal surgery. In an alternate scenario, if this patient had only undergone superficial parotidectomy, she would have been treated as stage IV

Full access

Presenters: Crystal S. Denlinger, Kristina A. Matkowskyj, and Mary F. Mulcahy

newly diagnosed patients, postoperative therapy with nivolumab after preoperative chemoradiation and surgery in patients who have achieved R0 resections but have residual disease is a category 1 recommendation. For the first-line treatment of advanced